In addition to PF-03732010, tumor treatments targeting P-cadherin have been challenged for PF-06671008 (bispecific antibody against P-cadherin and CD3) (25) and PCA-062 (DM1 conjugated antibody) (NCT02375958). The gene discussed is CDH3; the disease is neoplasm.